Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 10,000 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) General Counsel David O. Watson sold 10,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $44.51, for a total transaction of $445,100.00. Following the completion of the sale, the general counsel now owns 115,569 shares of the company’s stock, valued at approximately $5,143,976.19. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Apellis Pharmaceuticals stock traded up $3.02 during mid-day trading on Thursday, reaching $47.00. The company’s stock had a trading volume of 1,031,467 shares, compared to its average volume of 1,063,929. Apellis Pharmaceuticals, Inc. has a 12-month low of $27.50 and a 12-month high of $73.00. The company has a quick ratio of 8.58, a current ratio of 8.85 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $43.83 and its two-hundred day moving average price is $44.95.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative net margin of 866.81% and a negative return on equity of 607.37%. During the same quarter in the previous year, the business earned ($2.32) earnings per share. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -5.56 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its stake in Apellis Pharmaceuticals by 25.4% in the 4th quarter. Arizona State Retirement System now owns 20,617 shares of the company’s stock valued at $975,000 after buying an additional 4,172 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Apellis Pharmaceuticals by 61.6% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 26,074 shares of the company’s stock valued at $1,233,000 after purchasing an additional 9,938 shares during the period. Asymmetry Capital Management L.P. bought a new position in Apellis Pharmaceuticals in the 4th quarter valued at $6,593,000. Rhumbline Advisers boosted its holdings in Apellis Pharmaceuticals by 6.5% in the 4th quarter. Rhumbline Advisers now owns 73,929 shares of the company’s stock valued at $3,495,000 after purchasing an additional 4,534 shares during the period. Finally, Walleye Capital LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter valued at $5,443,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

APLS has been the subject of several analyst reports. The Goldman Sachs Group decreased their price objective on shares of Apellis Pharmaceuticals from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. Credit Suisse Group increased their price objective on shares of Apellis Pharmaceuticals to $49.00 in a research note on Friday, May 20th. Stifel Nicolaus assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, June 16th. They issued a “buy” rating for the company. Raymond James decreased their price target on shares of Apellis Pharmaceuticals from $114.00 to $102.00 in a research note on Thursday, May 5th. Finally, Citigroup restated a “focus list” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Thursday, March 17th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.64.

About Apellis Pharmaceuticals (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Featured Articles

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.